Aleksandra Yosifova
A5015753691- PARP inhibition in cancer therapy
- Ovarian cancer diagnosis and treatment
- Cancer Genomics and Diagnostics
Princess Margaret Cancer Centre
2023
University Health Network
2023
To evaluate the use of blood cell-free DNA (cfDNA) to identify emerging mechanisms resistance PARP inhibitors (PARPi) in high-grade serous ovarian cancer (HGSOC).
<p>Supplementary Figure 5: Sensitivity of variant calling methods on cfDNA</p>
<p>Supplementary Figure 3: Distribution of ctDNA levels and statistical association with clinical features</p>
<p>Supplementary Figure 3: Distribution of ctDNA levels and statistical association with clinical features</p>
<p>Supplementary Figure 7: Copy-number profile of CCNE1 in cfDNA</p>
<div>Abstract<p>Purpose To evaluate the use of blood cell-free DNA (cfDNA) to identify emerging mechanisms resistance PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Patients and Methods We used targeted sequencing (TS) analyse 78 longitudinal cfDNA samples collected from 30 patients with HGSOC enrolled a phase II clinical trial evaluating cediranib (VEGF inhibitor) plus olaparib after progression on PARPi alone. was at baseline, before treatment cycle 2, end...
<p>Supplementary Figure 4: Distribution of cfDNA fragment length</p>
<p>Supplementary Figure 1: Establishment of limit detection (LOD) for targeted sequencing panel on ctDNA</p>
<p>Supplementary Figure 5: Sensitivity of variant calling methods on cfDNA</p>
<p>Supplementary Figure 6: Visualization of structural variants in cfDNA</p>
<p>Supplementary Figure 1: Establishment of limit detection (LOD) for targeted sequencing panel on ctDNA</p>
<p>Supplementary Figure 7: Copy-number profile of CCNE1 in cfDNA</p>
<p>Supplementary Figure 2: Estimated tumour content in plasma DNA</p>
<p>Supplementary Figure 4: Distribution of cfDNA fragment length</p>
<p>Supplementary Figure 6: Visualization of structural variants in cfDNA</p>
<p>Supplementary Figure 2: Estimated tumour content in plasma DNA</p>